Mark W Ball1, Stephania M Bezerra2, Alcides Chaux3, Sheila F Faraj2, Nilda Gonzalez-Roibon2, Enrico Munari2, Rajni Sharma2, Trinity J Bivalacqua4, George J Netto5, Arthur L Burnett4. 1. The James Buchanan Brady Urological Institute & Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: mark.ball@jhmi.edu. 2. Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD. 3. Norte University, Office of Scientific Research, Asunción, Paraguay. 4. The James Buchanan Brady Urological Institute & Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD. 5. The James Buchanan Brady Urological Institute & Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD; Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
OBJECTIVE: To evaluate insulin-like growth factor-1 receptor (IGF1R) expression in penile cancer and its association with oncologic outcomes. METHODS: Tissue microarrays were constructed from 53 patients treated at our institution. Expression of IGF1R was evaluated using a Her2-like scoring system. Overexpression was defined as 1+ or greater membranous staining. Association of IGF1R expression with pathologic features was assessed with comparative statistics, and association with local recurrence, progression to nodal or distance metastases, or death was assessed with Kaplan-Meier survival analysis and Cox proportional hazard regression models. RESULTS: Overall, IGF1R overexpression was seen in 33 (62%) cases. With a median follow-up of 27.8 months, IGF1R overexpression was associated with inferior progression-free survival (PFS) (P = .003). In a multivariable model controlling for grade, T stage, perineural invasion, and lymphovascular invasion, IGF1R expression was independently associated with disease progression (hazard ratio 2.3, 95% confidence interval 1.1-5.1, P = .03. Comparing patients without IGF1R overexpression to those with overexpression, 5-year PFS was 94.1% vs 45.8%. CONCLUSION: IGF1R overexpression was associated with inferior PFS in penile cancer. Drugs that target IGF1R and downstream messengers may have a therapeutic benefit in patients that exhibit IGF1R overexpression.
OBJECTIVE: To evaluate insulin-like growth factor-1 receptor (IGF1R) expression in penile cancer and its association with oncologic outcomes. METHODS: Tissue microarrays were constructed from 53 patients treated at our institution. Expression of IGF1R was evaluated using a Her2-like scoring system. Overexpression was defined as 1+ or greater membranous staining. Association of IGF1R expression with pathologic features was assessed with comparative statistics, and association with local recurrence, progression to nodal or distance metastases, or death was assessed with Kaplan-Meier survival analysis and Cox proportional hazard regression models. RESULTS: Overall, IGF1R overexpression was seen in 33 (62%) cases. With a median follow-up of 27.8 months, IGF1R overexpression was associated with inferior progression-free survival (PFS) (P = .003). In a multivariable model controlling for grade, T stage, perineural invasion, and lymphovascular invasion, IGF1R expression was independently associated with disease progression (hazard ratio 2.3, 95% confidence interval 1.1-5.1, P = .03. Comparing patients without IGF1R overexpression to those with overexpression, 5-year PFS was 94.1% vs 45.8%. CONCLUSION:IGF1R overexpression was associated with inferior PFS in penile cancer. Drugs that target IGF1R and downstream messengers may have a therapeutic benefit in patients that exhibit IGF1R overexpression.
Authors: Jin-Soo Kim; Edward S Kim; Diane Liu; J Jack Lee; Luisa Solis; Carmen Behrens; Scott M Lippman; Waun Ki Hong; Ignacio I Wistuba; Ho-Young Lee Journal: Cancer Date: 2011-09-22 Impact factor: 6.860
Authors: Rodolphe Thuret; Maxine Sun; Firas Abdollah; Lars Budaus; Giovanni Lughezzani; Daniel Liberman; Monica Morgan; Rupinder Johal; Claudio Jeldres; Mathieu Latour; Shahrokh F Shariat; François Iborra; Jacques Guiter; Jean-Jacques Patard; Paul Perrotte; Pierre I Karakiewicz Journal: J Urol Date: 2010-12-17 Impact factor: 7.450
Authors: Eric K Rowinsky; Jonathan D Schwartz; Naseem Zojwalla; Hagop Youssoufian; Floyd Fox; Philippe Pultar; Ruslan Novosyadlyy; Jan Cosaert; Dale L Ludwig Journal: Curr Drug Targets Date: 2011-12 Impact factor: 3.465
Authors: F Cappuzzo; G Tallini; G Finocchiaro; R S Wilson; C Ligorio; L Giordano; L Toschi; M Incarbone; R Cavina; L Terracciano; M Roncalli; M Alloisio; M Varella-Garcia; W A Franklin; A Santoro Journal: Ann Oncol Date: 2009-09-18 Impact factor: 32.976
Authors: Sheila F Faraj; Nilda Gonzalez-Roibon; Enrico Munari; Rajni Sharma; Arthur L Burnett; Antonio L Cubilla; George J Netto; Alcides Chaux Journal: Virchows Arch Date: 2017-03-27 Impact factor: 4.064